Dexmedetomidine in Cardiac surgical intraoperative drug evaluation (DECIDE): a triple-blind, placebo-controlled, randomised trial evaluating whether dexmedetomidine improves: cognition, days alive and coma free in patients aged 65 years or older.

niversity of Sydney0 个研究点目标入组 1,100 人开始时间: 2023年11月13日最近更新: 2024年2月27日

适应症

试验速览

暂无简介。

•1.Adults undergoing cardiac surgery with cardiopulmonary bypass
•2.Age 65 years and older
•3.Sufficient English language to complete the cognitive testing in the opinion of the research team
•4.Willing and able to comply with all study requirements, including treatment, timing, and assessments.

•1.Dementia (pre-existing confirmed clinical diagnosis)
•2.Known allergy to Dexmedetomidine (DEX)
•3.Second or third-degree heart block
•4.Heart rate less than 55 unless on concomitant beta blockade
•5.Renal dialysis within 30 days of surgery
•6.Life expectancy of less than 30 days regardless of surgery
•7.Preoperative mechanical support other than intra-aortic balloon pump
•8.Salvage surgery requiring cardiopulmonary resuscitation
•9.Child-Pugh class C liver Cirrhosis
•10.Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the study procedures.
•11.Hearing loss, or medical or psychiatric condition that could preclude the ability of the patient to comply with study procedures.
•12.Prior enrolment in DECIDE trial in prior 12 months.

发起方